SVT 4A1011
Alternative Names: SVT-4A1011Latest Information Update: 24 Oct 2022
Price :
$50 *
At a glance
- Originator Servatus Biopharmaceuticals
- Class Bacteria; Skin disorder therapies; Sleep disorder therapies
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Insomnia
Most Recent Events
- 01 Oct 2022 Servatus Biopharmaceuticals plans a phase I/II trial in Insomnia in Australia (PO), In February 2022 (ACTRN12621001413819p) (Servatus Biopharmaceuticals pipeline, October 2022)
- 23 Sep 2022 Phase-I/II clinical trials in Insomnia in Australia (PO) (ACTRN12621001413819p) (Servatus Biopharmaceuticals pipeline, March 2023)
- 14 Oct 2021 Phase-I clinical trials in Insomnia in Australia (unspecified route) (Servatus Biopharmaceuticals pipeline, October 2021)